THIS IS THE SVF-2
The SVF-2 presents a major step forward for cellular therapy. In as little as 60 minutes, a small sample of tissue is used to create a cellular implant for targeted therapy.
INTRODUCING THE SVF-2
The SVF-2 uniquely harvests and isolates a patient’s own stromal and vascular cells, including stromal progenitor cells, to help control pain, reduce inflammation and repair inflamed tissues in the osteoarthritic knee. FDA Phase II clinical trials for this minimally invasive procedure have shown no serious adverse events and significant improvements in pain, stiffness and function (see results of the clinical study here: AJSM Phase IIb ).
MUSCULOSKELETAL THERAPIES
Therapies designed to reduce pain and improve mobility using cellular implants of your own cells.
COMING SOON
Further clinical trials are already or will soon be underway to prove the SVF-2’s effectiveness in the treatment of osteoarthritis and rheumatoid arthritis throughout the body.
PENDING APPROVAL
The SVF-2 has been proven effective in the treatment of osteoarthritis in the knee and has been submitted to the FDA for approval.
DERMAL THERAPIES
Repair and reconstruct dermal tissues such as non-healing wounds and diabetic foot ulcers resulting from peripheral vascular disease/diabetes.
COMING SOON
Clinical trials of the SVF-2ʼs effectiveness in treating peripheral vascular disease in small & large vessels, diabetic ulcers, and volume augmentation have already been completed, with more coming soon.
COMING SOON
Trials in long covid, CPD, and kidney fibrosis are already underway.
ORGAN THERAPIES
Repair vascular organ function with cellular therapies being developed to address fibrosis and ischemia in lungs, kidneys, and the liver.
PIPELINE OVERVIEW
PRE-CLINICAL
SAFETY/FEASIBILITY
PIVOTAL SAFETY/EFFICACY
FDA MARKET APPROVAL
OSTEOARTHRITIS KNEE
The osteoarthritis trial is a multi-site pivotal clinical trial that is double-blinded, randomized, placebo-controlled, dose-escalated, and statistically powered. The trial has IDE and is compliant with FDA regulations.
Near-term
WOUND CARE/SCAR MANAGEMENT
Human Data for Diabetic Ulcers - Pilot
OSTEOARTHRITIS EXTREMITIES
Human Data for Hands - Pilot
Longer-term
LUNG/COVID (SECONDARY/LONG)
Human Data in development - pilot
PARKINSON'S DISEASE
Human Data in development - pilot
THIS IS THE SVF-2
The SVF-2 presents a major step forward for cellular therapy. In as little as 60 minutes, a small sample of tissue is used to create a cellular implant for targeted therapy.
INTRODUCING THE SVF-2
The SVF-2 uniquely harvests and isolates a patient’s own stromal and vascular cells, including stromal progenitor cells, to help control pain, reduce inflammation and repair inflamed tissues in the osteoarthritic knee. FDA Phase II clinical trials for this minimally invasive procedure have shown no serious adverse events and significant improvements in pain, stiffness and function (see results of the clinical study here: AJSM Phase IIb ).
MUSCULOSKELETAL THERAPIES
Therapies designed to reduce pain and improve mobility using cellular implants of your own cells.
COMING SOON
Further clinical trials are already or will soon be underway to prove the SVF-2’s effectiveness in the treatment of osteoarthritis and rheumatoid arthritis throughout the body.
PENDING APPROVAL
The SVF-2 has been proven effective in the treatment of osteoarthritis in the knee and has been submitted to the FDA for approval.
DERMAL THERAPIES
Repair and reconstruct dermal tissues such as non-healing wounds and diabetic foot ulcers resulting from peripheral vascular disease/diabetes.
COMING SOON
Clinical trials of the SVF-2ʼs effectiveness in treating peripheral vascular disease in small & large vessels, diabetic ulcers, and volume augmentation have already been completed, with more coming soon.
ORGAN THERAPIES
Repair vascular organ function with cellular therapies being developed to address fibrosis and ischemia in lungs, kidneys, and the liver.
COMING SOON
Trials in long covid, CPD, and kidney fibrosis are already underway.
OSTEOARTHRITIS KNEE
The osteoarthritis trial is a multi-site pivotal clinical trial that is double-blinded, randomized, placebo-controlled, dose-escalated, and statistically powered. The trial has IDE and is compliant with FDA regulations.
Near Term
WOUND CARE/SCAR MANAGEMENT
Human Data for Diabetic Ulcers - Pilot
OSTEOARTHRITIS EXTREMITIES
Human Data for Hands - Pilot
Longer Term
LUNG/COVID (SECONDARY/LONG)
Human Data for Hands - Pilot
PARKINSONS
Human Data for Hands - Pilot
